NCT02619162View on ClinicalTrials.gov

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

June 30, 2018

Conditions
Breast Cancer
Interventions
DRUG

Nintedanib

Tablets of 100 mg. or 150 mg.

DRUG

Letrozole

Tablet of 2.5 mg.

Trial Locations (3)

28006

Hospital de La Princesa, Madrid

28223

Clínica Quirón, Madrid

28942

Hospital Universitario de Fuenlabrada, Fuenlabrada

All Listed Sponsors
collaborator

Dr. Miguel Angel Quintela Fandiño (CNIO)

UNKNOWN

collaborator

Dr, Ramón Colomer i Bosch

UNKNOWN

collaborator

FUNDACIÓN CRIS (Marta Cardona) as promotor

UNKNOWN

lead

Centro Nacional de Investigaciones Oncologicas CARLOS III

OTHER

NCT02619162 - Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics | Biotech Hunter | Biotech Hunter